Immune cell function assay in pediatric heart transplant recipients

Area of Science:

• Immunology
• Transplantation
• Pediatric Medicine

Background:

• The ImmuKnow assay (Immune ચેક Flow Cytometry Assay - ICFA) quantifies immunosuppression by measuring ex vivo CD4+ lymphocyte activation.
• Limited organ- and age-specific data exist for pediatric heart transplant recipients regarding ICFA values.
• Understanding normative ICFA values is crucial for monitoring immunosuppression in this population.

Purpose of the Study:

• To establish normative ex vivo CD4+ lymphocyte activation (ICFA) values in pediatric heart transplant recipients.
• To investigate the association between ICFA levels and the risk of rejection or infection.
• To compare established pediatric ICFA ranges with manufacturer-suggested values.

Main Methods:

• Retrospective analysis of 380 ICFAs from 58 pediatric heart transplant recipients.
• Data collection included ICFA levels during periods of immunologic stability, rejection, and infection.
• Statistical analysis to determine normative ranges, age- and time-related trends, and correlations with clinical outcomes.

Main Results:

• Normative ICFA levels during immunologic stability in pediatric heart recipients (median 305 ng ATP/mL) differed significantly from manufacturer ranges.
• ICFA levels demonstrated an inverse relationship with patient age and increased over time post-transplant (after six months).
• No significant association was found between ICFA values during stability and subsequent rejection or infection events.

Conclusions:

• Pediatric heart transplant recipients exhibit distinct normative ICFA ranges that vary with age and time post-transplant.
• The ImmuKnow assay (ICFA) did not demonstrate the ability to discriminate between immunologic stability, rejection, or infection in this cohort.
• Current manufacturer ranges for ICFA may not be directly applicable to pediatric heart transplant recipients.